USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 76 – 100 of 126 Awards
Company: TRANSGENEX NANOBIOTECH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … According to estimates by the Joint United Nations Program on HIV/AIDS (UNAIDS), approximately 40 million people will be living with HIV/AIDS worldwide by the end of 2006. However, safe and effective AIDS vaccine remain s difficult to develop. Small interference RNA (siRNA)… more
Company: APOLLO SRI, LLC Agency/Program/Year/Phase: HHS / STTR / 2007 / 1
Abstract: DESCRIPTION (provided by applicant): Our research is focused on the potential of acid-prepared mesoporous silica (APMS) as a delivery agent for siRNA constructs to inhibit the ERK1/2 and ERK5 pathways in the treatment of human malignant mesothelioma (MM). These pathways are… more
Company: AviGenics Inc. Agency/Program/Year/Phase: NSF / SBIR / 2007 / 1
Abstract: … equipment. RNAi technology is a new strategy that could be applied to the inhibition of AI virus replication, representing a paradigm shift in the way to deal with the challenges of AI. Phase I objectives are (i) to generate ALV vectors hosting short interfering RNA (siRNA), … more
Company: BIOSURFACES Agency/Program/Year/Phase: NSF / STTR / 2007 / 1
Abstract: This Small Business Technology Transfer (STTR) Phase I research project aims to develop a fibrous material for the embedment and gradual release of appropriate genetic material, including small interfering RNA (siRNA), and viral vectors carrying genes for anti-inflammatory… more
Company: CELLECTA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2007 / 1
Abstract: … this library in a simple cell culture-based model, to identify genes responsible for the growth limiting actions of TGF-a in cancer cells. In Phase II, we will extend this program to include the developme nt of genome-wide functionally validated human and mouse siRNA… more
Company: CELLECTA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2007 / 2
Abstract: …ram to include the development of databases comprising a genome-wide FV mouse shRNAs without off-target activity. The FV shRNA databases will be used to develop and release as a commercial product FV shRNA librarie s cloned into lentiviral vectors. Genetic screens with FV siRNA… more
Company: FLUXION BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2007 / 2
Abstract: …tions that our system can uniquely address are: (1) drug safety testing via hERG screening (2) inte grated transfection of an ion channel construct and ion channel recordings via patch clamp measurements and (3) intracellular delivery of short interfering RNA (siRNA) for target… more
Company: IBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2007 / 2
Abstract: … cells, the widespread application of RNAi technology to gene inhibition in animals remains elusive. This is largely due to the poor pharmacokinetic (PK) properties of RNAi based drugs such as small interfering RNAs (siRNAs). We bel ieve that that unmodified siRNA will… more
Company: MIRUS BIO CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2007 / 1
Abstract: DESCRIPTION (provided by applicant): This project aims to identify peptides that can be used to target drugs (small molecules, biologicals, DNA, siRNA) specifically to liver tumor cells. We will use phage display selection techniques to identify such pepti des. The incidence of… more
Company: MIRUS BIO CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2007 / 2
Abstract: … acids molecules to hepatocytes remains to be perfected. From the Phase I studies, a synthetic peptide that enabled efficient hepatocyte targeted delivery in mice of a variety of proteins, and particles such as liposomes an d most importantly, polycation-condensed DNA or siRNA… more
Company: MIRUS BIO CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2007 / 2
Abstract: … molecules to hepatocytes remains to be perfected. To date, most in vivo nucleic acid delivery vehicles have been colloid pa rticles with size grater than 50 nm. We believe that we have found an innovative strategy for the delivery of molecular conjugates of siRNA. This… more
Company: Omm Scientific, Inc Agency/Program/Year/Phase: HHS / SBIR / 2007 / 1
Abstract: … purity; (b) high yield couplings (gt99%) in the synthesis of se veral oligo-RNAs and (c) high yield deprotection (gtXX%) of these oligos using NaIO4. Accomplishing the specific aims will show feasibility from monomer synthesis to biological activity of an siRNA. First, at… more
Company: PROGENRA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2007 / 1
Abstract: … deubiquitinati ng enzyme AMSH abrogates this effect by removing ubiquitin from EGFR, permitting it to recycle to the membrane and retain its ability to regulate cell growth and division. It has been shown that purified AMSH removes ubiquitin from EGFR in vitro, and that … more
Company: VASCULAR VISION PHARMACEUTICALS COMPANY Agency/Program/Year/Phase: HHS / STTR / 2007 / 1
Abstract: …nce ultimately exhibit resistance to chemotherapy. Recent reports provide a persuasive rationale for studying the role of cathepsin L in the process of chemotherapeutic drug resistance. We showed that specific targeting of cathepsin L using chemical inhibitors or siRNA to this… more
Company: ALNYLAM PHARMACEUTICALS Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: … RNA interference. To achieve this goal we will design, synthesize and test a pool of chemically optimized siRNAs targeting highly conserved flu gene sequences by in vitro and in vivo screens against low and highly pathogenic flu strains, including H5N1. Importantly, our … more
Company: CALANDO PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: …ing by RNA interference (RNAi) is rapidly becoming the method of choice for the elucidation of gene function and the identification of therapeutic targets. RNAi is envisioned to ultimately be used as a potent and selective human therapeutic. Short interfering RNAs (siRNA) can be… more
Company: GENESEGUES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: DESCRIPTION (provided by applicant): The prospect of using siRNAs as potent inhibitors to any gene of choice may provide a new therapeutic approach for many intractable diseases. However, a major impediment to successful development of siRNA-based therapies has been the general… more
Company: IBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: … cells, the widespread application of RNAi technology to gene downregulation in animals remains elusive. This is largely due to the poor pharmacokinetic (PK) properties of RNAi based drugs such as small interfering RNAs (siRNAs). We believe that that unmodified siRNA will… more
Company: INTRONN, INC. Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: DESCRIPTION (provided by applicant): Although RNA interference (RNAi) technology has revolutionized the process of rapidly and efficiently generating models to study disease, it has been limited by the lack of robust control over short interfering or micro RNA (siRNA/miRNA)… more
Company: MUREX PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / STTR / 2006 / 1
Abstract: …cogene plays diverse roles in the oncogenetic initiation and maintenance events. K-ras knockdown by the siRNAras transgene transcript is expected to promote tumor cell growth inhibition and apoptosis at the late phase of viral replication. The strategy of restricting siRNA… more
Company: PROGENRA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: … has also been identified as playing an integral role in cancer as it is induced in human breast cancer cell lines and primary tumor samples. Further evidence suggests a role for (a-TrCP in tumor progression, as a-TrCP knockout mice are hypoplastic. Ablation of a-TrCP via siRNA… more
Company: SOMAGENICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2006 / 1
Abstract: DESCRIPTION (provided by applicant): Both short interfering RNA (siRNA) and short hairpin RNA (shRNA) are potent gene-silencing agents that have been successfully used in cell culture. However, so far their application in vivo has been limited by the low stability of RNA and… more
Company: SYSTEM BIOSCIENCES, LLC (SBI) Agency/Program/Year/Phase: HHS / SBIR / 2006 / 2
Abstract: …of individual constructs will be performed by screening the high complexity transcriptional reporter library against an array of different cell lines treated by different therapeutic and signal transducing agents and by knockdown of specific transcriptional factors by siRNA… more
Company: AMBION DIAGNOSTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2005 / 1
Abstract: DESCRIPTION (provided by applicant): Small interfering RNA (siRNA) specifically degrades target complementary mRNAs in cells. The vector system that controls the expression of siRNAs has been widely used for academic research and clinical therapy. Although Pol III promoters are… more
Company: Genpathway, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2005 / 2
Abstract: … activities of genes by identifying and quantifying complexes containing genomic DNA and transcription-associated proteins. In the proposed Phase II studies, TranscriptionPath will be applied to 3 model systems reproducing key aspects of the MLIV disease: (1) siRNA inhibition of… more
Displaying 76 – 100 of 126 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.